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Background: The dopamine D3 receptor can form dimers/oligomers, but the molecular basis for this is poorly defined.
Results: Molecular modeling, mutagenesis, and analysis of inactive state receptor crystal structures allowed assessment of
models of receptor organization.
Conclusion: The dopamine D3 receptor can assume different dimeric and a rhombic tetrameric arrangements.
Significance: These findings provide understanding of the molecular basis of D3 receptor quaternary structure.
The dopamine D3 receptor is a class A, rhodopsin-like G pro-
tein-coupled receptor that can form dimers and/or higher order
oligomers. However, themolecular basis for production of these
complexes is not well defined. Using combinations ofmolecular
modeling, site-directedmutagenesis, and homogenous time-re-
solved FRET, the interfaces that allow dopamine D3 receptor
monomers to interact were defined and used to describe likely
quaternary arrangements of the receptor. Thesewere then com-
pared with published crystal structures of dimeric1-adrenore-
ceptor, -opioid, and CXCR4 receptors. The data indicate
important contributions of residues from within each of trans-
membrane domains I, II, IV, V, VI, and VII as well as the intra-
cellular helix VIII in the formation of D3-D3 receptor interfaces
within homo-oligomers and are consistent with the D3 receptor
adopting a 1-adrenoreceptor-like quaternary arrangement.
Specifically, results suggest that D3 protomers can interact with
each other via at least two distinct interfaces: the first one com-
prising residues from transmembrane domains I and II along
with those from helix VIII and a second one involving trans-
membrane domains IV and V. Moreover, rather than existing
only as distinct dimeric species, the results are consistent with
the D3 receptor also assuming a quaternary structure in which
two transmembrane domain I-II-helix VIII dimers interact to
form a ”rhombic” tetramer via an interface involving residues
from transmembrane domains VI and VII. In addition, the
results also provide insights into the potential contribution of
molecules of cholesterol to the overall organization and poten-
tial stability of theD3 receptor and possibly other GPCR quater-
nary structures.
It is nowwell accepted that, as well asmembers of the class C,
glutamate receptor family, class A, rhodopsin-like G protein-
coupled receptors (GPCRs)5 can form dimers and/or higher
order oligomers (1–3). Based on this, there is great interest in
how such protein-protein interactions might modulate impor-
tant functions of these GPCRs including maturation, ligand
pharmacology, signaling and trafficking (4, 5). The overarching
seven transmembrane domain (TMD) architecture of GPCRs
and the similarity of the overall domain fold of class A GPCRs
observed in various crystal structures suggests potentially con-
served interaction interfaces. However, despite numerous
molecular, biochemical, and biophysical studies, the molecular
basis underlying class A GPCR dimerization and/or oligomer-
ization is unclear and lacks a single unifying hypothesis. Thus,
for different family members a range of contact interfaces has
been suggested (1–3). Moreover, the capacity to exist as higher
order oligomers suggests that multiple contact sites must be
present to produce this organization.
Receptors for the neurotransmitter dopamine are GPCRs
belonging to the class A family. They are separated into two
broad groups based on their principal signaling mechanisms
and distribution. The D1-like receptors (D1 and D5) are mainly
coupled to stimulatory G proteins and enhance the activity of
adenylyl cyclases, whereas D2-like receptors (D2, D3, and D4)
are largely coupled to inhibitory G proteins and suppress the
activity of adenylyl cyclases andmodulate a variety of ion chan-
nels (6). Dysregulation of dopaminergic neurotransmission in
the substantia nigra and in the striatum is implicated in multi-
ple disorders including Parkinson disease, attention deficit
hyperactivity disorder, and a group of psychotic disorders
including schizophrenia (6). The dopaminergic hypothesis of
schizophrenia suggests that this reflects excessive central dop-
aminergic activity due to changes in dopamine receptors rather
than a quantitative change in neuronal dopaminergic activity
(7). Conditions such as schizophrenia are treated routinely
using ligands with antagonist affinity at the D2 receptor, but
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interestingly, many of these actually have moderate selectivity
for the D3 receptor over the D2 receptor (8–10). Moreover,
because of the overlap of ligand recognition between theD2 and
D3 receptors and co-expression of the two receptors in caudate,
putamen, and striatum, their individual contributions are chal-
lenging to define (11, 12).
Adding complexity to this system is the capability of both D2
andD3 receptors to form homo- and hetero-oligomers that can
also influence dopaminergic neurotransmission (12, 13). Inter-
estingly, in schizophrenia alterations in the proportion of D2
receptor monomers versus dimers and homomeric D3 com-
plexes have been reported (14). Importantly, recent studies
indicate that each of these species can co-exist concurrently
(15).
Although the capacity of the D2 receptor to form ho-
modimers and higher order oligomers has been studied exten-
sively (16–18), less is known about D3 receptor homo interac-
tions. The D3 receptor is of particular interest as it has been
identified as a potential target for drug discovery in the field of
drug addiction (19). In the current studies we have employed
molecular modeling based on a high resolution, inactive state
structure of the human D3 (hD3) receptor complexed with the
antagonist eticlopride (20) to generate different potential mod-
els of this receptor in a dimeric arrangement. These models
were then assessed after alanine mutagenesis of residues that
the models indicated to be potentially involved in dimer inter-
faces. Homogenous time resolved-FRET (htrFRET) using Tag-
LiteTM technology (21) was employed to monitor alterations in
the capability of eachmutant to form homomers. These studies
investigated the roles of regions of TMDs I, II, IV, V, VI, andVII
aswell as the intracellular helix VIII in the formation of possible
interfaces within hD3-hD3 receptor homo-oligomers. The
results obtained are consistent with hD3 receptor monomers
being able to interact with each other via at least two interfaces
of dimerization: the first composed by residues from TMD I
and TMD II as well as helix VIII and the second consisting of
residues within TMDs IV and V. Furthermore, the data are
consistent with the hD3 receptor assuming a higher order qua-
ternary structure in which two TMD I-II-helix VIII dimers
interact to form a rhombic tetramer via an interface involving
residues fromTMDsVI andVII. Interestingly, these results also
provide insights into the potential contribution of molecules of
cholesterol to the overall organization and potential stability of
this, and possibly other, GPCRs quaternary structures.
Materials andMethods
DNA Constructs of the VSV- and SNAP-tagged Human Dop-
amineD3Receptor (VSV-SNAP-hD3)—Asdescribed previously,
the plasmid pSEMS1–26m (SNAP tag) (22), as supplied by
Covalys Biosciences AG (Witterswil, Switzerland), was modi-
fied by the addition of a small linker region encoding the
metabotropic glutamate receptor 5 signal sequence (MVLL-
LILSVLLLKEDVRGSAQS) and the VSV epitope tag (YTDI-
EMNRLGK) between the ClaI and EcoRI sites of the multiple
cloning site upstream of the SNAP tag (MCS1). The hD3 recep-
tor was PCR-amplified using primers designed to add BamHI
and NotI sites to the fragment termini. It was then ligated into
the multiple cloning site downstream of SNAP tag of the mod-
ified plasmid described above (15).
Mutagenesis of VSV-SNAP-hD3—The Stratagene QuikChange
method (Stratagene, Agilent Technologies, Santa Clara, CA)
was used to introduce alterations into VSV-SNAP-hD3. Prim-
ers utilized for mutagenesis were provided by MWG Operon
(Acton, UK). Template DNA was digested with DpnI to leave
only the newly synthesized mutated plasmid, and sequencing
was carried out to confirm the introduction of the alterations.
Cell Culture and Transient Transfection of HEK293T Cells—
Humanembryonic kidney (HEK) 293Tcellsweremaintained in
Dulbecco’s modified Eagle’s medium supplemented with 0.292
g/liter L-glutamine (Sigma), 1% penicillin/streptomycin mix-
ture (Sigma), and 10% heat-inactivated fetal bovine serum
(Gibco, Life Technologies) at 37 °C in a 5% CO2 humidified
atmosphere. HEK293T cells were transfected using polyethyl-
eneimine (Fluka Analytical, Poole, Dorset, UK). The day before
transfection 1 106 cells were plated into 60-mm dishes. Plas-
mid DNA was then combined with polyethyleneimine (in 1:6
ratio) in 250 l of 150 mM NaCl, thoroughly mixed, and incu-
bated for 10 min at room temperature. Cell medium was
changed, and the DNA-polyethyleneimine mixture was added
to the medium in a dropwise manner.
Cell Lysate Preparation—HEK293T cells transiently trans-
fected with the construct of interest were harvested in ice-cold
phosphate-buffered saline (PBS) and lysed in lysis buffer (150
mM NaCl, 0.01 mM Na2HPO4, 2 mM EDTA, 0.5% n-dodecyl--
D-maltoside (DDM), 5% glycerol, and supplementedwithCom-
plete protease inhibitors mixture (Roche Diagnostics)) on a
rotating wheel for 30 min at 4 °C. Samples were then centri-
fuged for 15 min at 21,000 g at 4 °C, aliquoted, and stored at
20 °C until required.
Treatment of Cell Lysates—Deglycosylation was performed
using peptide-N-glycosidase F (Roche Diagnostics) at a final
concentration of 0.05 unit/l for 2 h at 37 °C.
Immunoblotting Assays—Cell lysate samples prepared as
abovewere diluted to a final concentration of 2mgml1 in lysis
buffer. These were then diluted in Laemmli buffer (5 M urea,
0.17 M SDS, 0.4 M dithiothreitol, 50 mM Tris-HCl, pH 8.0, and
0.01% bromphenol blue) to a final concentration of 1 mgml1.
Samples were heated at 65 °C for 5 min. 20 g of protein from
each sample was loaded into wells of 4–12% BisTris gels
(NuPAGE, Invitrogen) and subjected to SDS-PAGE analysis
using NuPAGE MOPS SDS running buffer (NuPAGE, Invit-
rogen). After separation, the proteins were electrophoretically
transferred onto nitrocellulose membrane, which was then
blocked (5% fat-free milk powder in PBS supplemented with
0.1% Tween 20 (PBS-Tween)) for 1 h at room temperature on a
rotating shaker. The membrane was then incubated with
appropriate primary antibody in 5% fat-free milk powder in
PBS-Tween overnight at 4 °C on a rotating shaker. Anti-SNAP
antiserum (New England Biolabs Inc., Hitchin, UK) was diluted
1:2000 and anti--tubulin antiserum (Sigma) diluted 1:5000.
Subsequently, the membrane was washed (3  10 min with
PBS-Tween) and then incubated for 1 h with the appropriate
secondary antibody (horseradish peroxidase-linked donkey
anti-rabbit IgG (GE Healthcare) or horseradish peroxidase-
linked sheep anti-mouse (GE Healthcare) diluted 1:10,000 in
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5% fat-free milk powder in PBS-Tween. After washing (3 10
min with PBS-Tween), proteins were detected by enhanced
chemiluminescence (Pierce) according to the manufacturer’s
instructions.
Cell Membrane Preparation—HEK293T cells transiently
transfected with the construct of interest were harvested in ice-
cold PBS, and pellets of cells were frozen at80 °C for a mini-
mum of 30 min. These were subsequently thawed and resus-
pended in ice-cold 10 mM Tris, 0.1 mM EDTA, pH 7.4 (TE
buffer) supplemented with Complete protease inhibitors mix-
ture (Roche Diagnostics). Cells were homogenized on ice by 40
strokes of a glass on a Teflon homogenizer followed by centri-
fugation at 200 g for 10 min at 4 °C to remove unbroken cells
and nuclei. The supernatant fraction was transferred to ultra-
centrifuge tubes and subjected to centrifugation at 90,000  g
for 45 min at 4 °C. The resulting pellets were resuspended in
ice-cold TE buffer and passed through a 25-gauge needle 3
times before being assessed for protein concentration. Mem-
brane preparations were then aliquoted and stored at 80 °C
until required.
[3H]Spiperone Binding Studies onMembrane Preparations—
Binding studies were initiated by the addition of 15 g of cell
membrane protein (or 25 g for poorly expressed mutants) in
assay buffer (20 mM HEPES, 6 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 40 M ascorbic acid) to tubes containing [3H]spiperone
(PerkinElmer Life Sciences) (0.019–14 nM) for saturation bind-
ing studies. Nonspecific binding was determined by the addi-
tion of 10 M ()-butaclamol (Sigma). Reactions were incu-
bated for 2 h at 30 °C and terminated by rapid vacuum filtration
though GF/C glass fiber filters (AlphaBiotech, London, UK)
followed by 3 washes with ice-cold PBS. The level of radioactiv-
ity associated with the filters was quantified using a Tri-Carb
2910 TR scintillation counter (PerkinElmer Life Sciences).
htrFRET Studies—Cells transfected with varying amounts of
construct cDNA were grown to 100,000 cells per well in solid
black 96-well plates (Greiner Bio-One Ltd, Stonehouse, UK)
coated with 0.1 mgml1 poly-D-lysine (Sigma). The htrFRET
assays were conducted using Tag-LiteTM reagents (Cisbio Bio-
assays, Bagnols-sur-Cèze, France). Briefly, growthmediumwas
replaced with 50l of amixture containing the defined optimal
concentrations of Tag-LiteTM SNAP-Lumi4-Tb (10 nM) (as
energy donor) and Tag-LiteTM SNAP-Red (100 nM) (as energy
acceptor). Plates were incubated for 1 h at 37 °C in a humidified
atmosphere (5% CO2), and subsequently washed four times in
labeling medium (Cisbio Bioassays). Plates with 100 l/well of
fresh labeling mediumwere then read on a PheraStar FS (BMG
Labtech, Ortenberg, Germany) htrFRET compatible reader.
Both the emission signal from the Tag-LiteTM SNAP-
Lumi4-Tb cryptate (620 nm) and the FRET signal emanating
from the acceptor Tag-LiteTM SNAP-Red (665 nm) were
recorded after excitation at 337 nm (23).
Computational Methods—A modification of the crystal
structure of hD3 receptor in complex with an antagonist (PDB
code 3PBL) (20) was used to build all the dimer and higher
oligomermodels. As theN-terminal of TMD I in hD3 crystals is
2 helix turns shorter than all other class A GPCR structures
released to date, Modeler 9v8 (24) was used to model a TMD I
as long as observed in the turkey 1-adrenoreceptor. All
released structures featuring cholesterol molecules (2-adre-
noreceptor, serotonin 5-HT2B receptor, adenosine A2A recep-
tor, -opioid receptor and the P2Y12 receptor) were super-
posed with the hD3model, and the cholesterol(s) was extracted
and added to hD3 models at the equivalent positions of the
structure. Dimers of hD3 with an interface including TMD I
were constructed based on those observed in the “dimer” crys-
tal structures of the inactive, mutationally stabilized turkey
1-adrenoreceptor (PDB code 4GPO) (25). Three different
dimers of hD3 with an interface including TMD V were based
on each of themouse-opioid receptor (26), on humanCXCR4
(27), and the turkey1-adrenoreceptor (25). Thesewere built as
dimerdimer, based on overall complementarily of shape, to
maximize the buried interface and to avoid contacts between
helices and then refined based on experimental data from the
mutagenesis studies. That GPCR dimers have room to couple
with only a single heterotrimeric G protein implies that a
tetramer should be able to interact simultaneously with two
functional heterotrimericG proteins to allow receptor-induced
GDP/GTP exchange. The Gs AH domain of the Gs subunit
within the heterotrimeric G protein (in “empty complex”)
undergoes a large rigid-body displacement (28) with respect to
its non-coupled GTP-bound form (29), and a similarly large
movement has also been reported in the Gi AH domain of the
Gi subunit (30). Thus, the nucleotide-free G protein requires
extra space compared with the GTP-bound conformation.
Tetramer models were considered as potentially valid only if
they both allowed the simultaneous binding of two heterotri-
meric G proteins in their nucleotide-free form, as in the atomic
level crystal of the 2-adrenoreceptor complexed with nucle-
otide-free Gs (PDB code 3SN6) (28) and could account for
experimental discrimination (at least simultaneous contribu-
tion of themain two “dimeric” interfaces, TMD I-TMD II-helix
VIII and TMD IV-TMD V). Modeling figures were generated
using PyMOL 1.5.3 (31). The “snake” plot was created using the
GPCR-SSFE database (32).
Data Analysis—Experiments were performed on at least
three independent occasions. All data were quantified and ana-
lyzed using GraphPad Prism 5.2. Where appropriate, data are
expressed as themean S.E. Statistical analysis was performed
by one-way analysis of variance with, where appropriate, the
addition of Dunnett’s test for multiple comparisons.
Results
In the last few years structures of various class AGPCRs have
been released as either asymmetric units of actual dimers (tur-
key 1-adrenoreceptor (25), -opioid receptor (33)) or with a
computationally estimated biological unit consistent with
dimeric organization (CXCR4 chemokine receptor (27),-opi-
oid receptor (26), 2-adrenoreceptor (34), and P2Y12 purino-
ceptor (35)). Each of these structures shows rather conserved
contact interfaces involving interactions between TMDs I, II,
and intracellular helix VIII (25, 26, 33). In contrast, less con-
served interfaces are observed on the other side of the receptor
TMD bundle, with TMD V-TMD VI interactions observed for
the -opioid receptor (26), TMD IV-TMD V interactions
observed in the 1-adrenoreceptor (25), and mainly TMD
V-TMD V interactions, with contributions from intracellular
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loop 2, observed in CXCR4 (27). It has been reported that the
hD3 can form functional dimers/oligomers (15, 36). To explore
the molecular basis of this we used the available crystal struc-
ture of hD3 complexed with the antagonist eticlopride (20) to
generate four dimeric models of hD3 (Fig. 1). These hypothe-
sized as interfaces (a) the broadly conserved TMD I, TMD II,
and helix VIII interactions (Fig. 1a) observed in many struc-
tures, including the 1-adrenoreceptor (25), (b) the TMD IV-V
interface as observed in the 1-adrenoreceptor structure (25)
(Fig. 1b), (c) the mainly TMD V-V interface observed in the
CXCR4 receptor (27) (Fig. 1c), and (d) a TMDV-VI interface as
observed for the -opioid receptor (26) (Fig. 1d).
To assess these models a series of htrFRET studies was per-
formed. Initially the hD3 receptor was modified at the extracel-
lular N terminus by incorporation of the metabotropic gluta-
mate receptor 5 signal sequence followed by the VSV epitope
tag and the SNAP variant of O6-alkylguanine-DNA-alkyltrans-
ferase. This generated the parental VSV-SNAP-hD3 construct
(15) (Fig. 2a). The SNAP tag sequence allows covalent incorpo-
ration of fluorophores into the expressed construct sequence
(21). This parental construct was used to transiently transfect
HEK293T cells. Lysate from these cells was resolved by SDS-
PAGE and immunoblottedwith anti-SNAP antiserum (Fig. 2b).
In such experiments a series of specific immunoreactive species
was observed with apparent molecular masses between 65 and
50 kDa. These appeared to represent differentially N-glycosy-
lated forms of VSV-SNAP-hD3 because pretreatment of the
lysatewith peptide-N-glycosidase F to removeN-linked glycans
resulted in these species being reduced to a single predominant
form that migrated more rapidly in SDS-PAGE (Fig. 2b). There
was also some evidence of immunoreactive species of substan-
tially lower mobility (Fig. 2b).
To assess cell surface delivery of VSV-SNAP-hD3, HEK293T
cells were transiently transfected with varying amounts of plas-
mid, and the cells then labeled with the cell impermeant fluo-
rophore SNAP-Lumi4-Tb (10 nM). Subsequent to excitation at
337 nm fluorescence emission at 620 nm, reflecting covalent
incorporation of Lumi4-Tb into the extracellular N-terminal
domain of VSV-SNAP-hD3, demonstrated that increasing lev-
els of cell surface expression of VSV-SNAP-hD3 were achieved
with increasing plasmid amount over the range assessed (Fig.
2c). Fluorescence emission at 620 nm was minimal in empty
plasmid-transfected cells (Fig. 2c), hence providing excellent
signal to background. To examine whether cell surface VSV-
SNAP-hD3 was present within dimer/oligomer structures,
htrFRETwas performed using Tag-LiteTM technology. Combi-
nations of SNAP-Lumi4-Tb (10 nM) as the energy donor and
varying concentrations of SNAP-Red as the energy acceptor
resulted in fluorescence emission at 665 nm, reflecting FRET,
after excitation at 337 nm. This is consistent with VSV-SNAP-
hD3displaying quaternary organization.As SNAP-Red concen-
trations were increased, the htrFRET signal initially increased,
reached a maximal level, and then subsequently declined (Fig.
2d). This is consistentwith higher concentrations of SNAP-Red
eventually out-competing the available SNAP-Lumi4-Tb for
binding to the cell surface population of VSV-SNAP-hD3 (Fig.
2d). When employing 10 nM SNAP-Lumi4-Tb, maximal
htrFRET was obtained with co-addition of 100 nM SNAP-Red
(Fig. 2d). This combination was then used routinely in subse-
quent studies. In a parallel set of experiments a modified ver-
sion of the single TMD epidermal growth factor receptor
(EGFR) containing both the VSV and SNAP tags at the extra-
cellular N-terminal region (VSV-SNAP-EGFR) and known to
be predominantly monomeric in the absence of agonist activa-
tion (37)was employed to define the htrFREToutput at 665-nm
reported hD3-hD3 interactions and not simply protein-protein
proximity because of the amount of receptor expressed. Tran-
sient transfectionwas optimized to achieve a similar cell surface
expression level of this construct, measured by emission at 620
nm after the addition of SNAP-Lumi4-Tb, as for VSV-SNAP-
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FIGURE 1. Molecular models of alternative hD3 receptor dimeric arrangements. hD3-hD3 interactions may be mediated by interfaces of dimerization
composed of residues from TMD I-II and helix VII as observed in a number of different receptors (a) and/or TMD IV-V interactions as observed in the turkey
1-adrenoreceptor (b). TMD V-V interactions, as observed in the CXCR4 chemokine receptor (c) or by TMD V-VI interactions (d), as observed in the -opioid
receptor.
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hD3 (Fig. 2d, inset). However, in these cells co-addition of a
range of concentrations of SNAP-Red resulted in very little
energy transfer (Fig. 2d).
After transfection of HEK293T cells with varying amounts of
VSV-SNAP-hD3 or VSV-SNAP-EGFR, growth in a 96-well
microtiter plate, and labeling with the optimized mixture of
SNAP-Lumi4-Tb (10 nM) and SNAP-Red (100 nM), fluores-
cence emission at 620 nm (indicative of cell surface expression
of the receptor construct) and 665 nm (reflecting protein-pro-
tein interactions) were then measured concurrently and corre-
lated. This produced a linear relationship, indicating constant
FRET efficiency over this range of receptor expression (Fig. 2e).
The slope that characterizes the linear regression generated
from VSV-SNAP-hD3 (2.78  0.034) or VSV-SNAP-EGFR
(1.12 0.049) (mean S.E.) was then considered to define the
quaternary structure illustrating, respectively, oligomeric and
monomeric status of the receptors.
We then used this methodology to consider the models
depicted in Fig. 1 with the aim of gaining insights into the most
likely organization for the quaternary structure of hD3. VSV-
SNAP-hD3 was used as the template to generate a variety of
alanine mutants within TMDs I, II, IV, V, VI, and VII as well as
in intracellular helix VIII (Fig. 3). As it was possible that certain
of the mutants might result in general unfolding and affect the
ligand binding pocket of VSV-SNAP-hD3, radioligand binding
studies were performed on key mutants. Saturation binding
studies were performed on membrane preparations from
transiently transfected HEK293T cells using the antagonist
[3H]spiperone, which has high affinity for the hD3 receptor.
Apart from the quadruple TMD I mutant, Ile-40,Leu-41,Val-
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FIGURE 2.Organization and expression of a SNAP-tagged formof hD3. a, schematic representation of hD3modified at theN terminus by the incorporation
of a signal sequence derived from the metabotropic glutamate receptor 5 (mGluR SS), the VSV epitope tag, and the SNAP-tag polypeptide to produce the
VSV-SNAP-hD3 construct. b, lysates from HEK293T cells transiently transfected with an empty vector or with VSV-SNAP-hD3 were resolved by SDS-PAGE after
previous treatment with () or without () peptide-N-glycosidase F (PNGase F) and immunoblotted (IB) with an anti-SNAP antiserum (upper panel) or an
anti--tubulin antiserum (lower panel). c, HEK293T cells transfectedwith increasing amounts of VSV-SNAP-hD3were incubatedwith the htrFRET energy donor
SNAP-Lumi4-Tb (10 nM). SNAP-Lumi4-Tb cell surface binding was determined by fluorescent emission at 620 nm and standardized for cell number. d, in cells
expressing VSV-SNAP-hD3 combinations of SNAP-Lumi4-Tb (10 nM) as energy donors and increasing concentrations of the htrFRET energy acceptor SNAP-Red
resulted in abell-shapeddistributionof resonance energy transfer (circles) fromSNAP-Lumi4-Tb to SNAP-Red. Equivalent experimentswereperformedon cells
expressing VSV-SNAP-EGFR (squares) at equal levels of cell surface expression as defined by binding and emission at 620 nm of SNAP-Lumi4-Tb (d, inset, open
barsmock transfection; filled bars corresponding receptor). e, htrFRET assays were performed on HEK293T cells transfected with increasing amounts of
VSV-SNAP-hD3 (circles) or VSV-SNAP-EGFR (squares) and labeled with an optimal combination of SNAP-Lumi4-Tb (10 nM) and SNAP-Red (100 nM). Cell surface
expression (signal at 620 nm) was plotted against energy transfer (signal at 665 nm).
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44,Phe-45 VSV-SNAP-hD3, [3H]spiperone displayed high
affinity binding similar to that of the wild type construct (range
of values: 0.24–2.47 nM) for each of the mutants subsequently
studied (Table 1).
To assess the model depicted in Fig. 1a, three quadruple
mutants inTMD I,Arg-27,His-29,Leu-34,Cys-37 (residue posi-
tions 1.30, 1.32, 1.37, and 1.40 in the Ballesteros andWeinstein
numbering system (38)) VSV-SNAP-hD3, Tyr-31,Tyr-32,Leu-
34,Ser-35 (1.34, 1.35, 1.37, 1.38) VSV-SNAP-hD3, and Ile-
40,Leu-41,Val-44,Phe-45 (1.43, 1.44, 1.47, 1.48) VSV-SNAP-
hD3 were generated. In addition, one quadruple mutant in
TMD II, Tyr-88,Val-91,Thr-92,Asn-97 (2.63, 2.66, 2.67, residue
97) VSV-SNAP-hD3, and each of a single, double, and a triple
mutant in helix VIII, Phe-394 (8.54) VSV-SNAP-hD3, Phe-
394,Leu-395 (8.54, 8.55) VSV-SNAP-hD3, and Phe-394,Leu-
395,Lys-396 (8.54, 8.55, 8.56) VSV-SNAP-hD3 (Fig. 3) were also
generated and studied. Lysates of HEK293T cells transfected
with each of these constructs were resolved by SDS-PAGE and
analyzed by immunoblotting with an anti-SNAP antiserum.
Tyr-31,Tyr-32,Leu-34,Ser-35 VSV-SNAP-hD3 and Phe-394
VSV-SNAP-hD3 produced a similar pattern of immunoreactive
bands and total expression as wild type VSV-SNAP-hD3. By
contrast, a reduction in the total expression level of Arg-27,His-
29,Leu-34,Cys-37 VSV-SNAP-hD3 and in the mature, fully
N-glycosylated form of the mutants Ile-40,Leu-41,Val-44,
Phe-45 VSV-SNAP-hD3, Tyr-88,Val-91,Thr-92,Asn-97 VSV-
SNAP-hD3, Phe-394,Leu-395 VSV-SNAP-hD3, and Phe-394,
Leu-395,Lys-396 VSV-SNAP-hD3 was noted (Fig. 4a). Cell sur-
face expression of each of these mutants was assessed by the
binding of SNAP-Lumi4-Tb (10 nM) and normalized for cell
number (Fig. 4b). As with many mutants of GPCRs, most of
these variants displayed reduced cell surface expression. In
particular, a marked reduction of both Ile-40,Leu-41,Val-
44,Phe-45 VSV-SNAP-hD3 and Tyr-88,Val-91,Thr-92,Asn-97
VSV-SNAP-hD3was observed at the cell surface, whereasmore
modest, but still significant, reduction of each of Arg-27,His-
29,Leu-34,Cys-37 VSV-SNAP-hD3, Phe-394,Leu-395 VSV-
SNAP-hD3, and Phe-394,Leu-395,Lys-396 VSV-SNAP-hD3
was recorded (Fig. 4b).
The positions of the residues in TMD I selected formutagen-
esis, based on the dimer models, are highlighted within the
atomic level structure of the hD3 monomer (Fig. 5A). Parallel
assessment of the ability of these mutants to maintain protein-
protein interactions and quaternary structure at the cell surface
was conducted via htrFRET assays performed on cells trans-
fected with varying amounts of each mutant and compared
directly to the wild type VSV-SNAP-hD3 construct. As for
VSV-SNAP-hD3, each of the TMD I mutants demonstrated
both a linear increase in cell surface expression with increasing
plasmid amount used to transfect the cells and, over this range,
a linear increase of the htrFRET signal at 665 nm (Fig. 5). This
indicated that each of the mutants was present within an olig-
omeric complex. However, the slope of the linear regression of
signal at 665 nm/signal at 620 nmwas reduced substantially for
Arg-27,His-29,Leu-34,Cys-37VSV-SNAP-hD3 (slope 0.74
0.06-fold of wild type; mean  S.E.) compared with wild type
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FIGURE 3. The topology of VSV-SNAP-hD3. All amino acids of hD3 receptor located within TMD I-TMD VII, extracellular loop 1, and helix VIII are shown and
designatedby the correspondingBallesteros-Weinstein residue locationnumber. Themost highly conserved residue in each TMD (X.50) is shown in a red circle.
VSV-SNAP-hD3 mutants were generated by alanine substitutions. Residues identified to be important for hD3-hD3 quaternary structure stability as defined in
htrFRET studies are shown in black circles, whereas residuesmodified that did not appear to be involved in the formation of a homomeric interface are shown
in gray circles.
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VSV-SNAP-hD3 (Fig. 5b). This indicates reduced proximity
between the hD3 receptor variant protomers and, hence, alter-
ation of receptor oligomer structure. Moreover, although Tyr-
31,Tyr-32,Leu-34,Ser-35 VSV-SNAP-hD3 did not show an
equivalent reduction in the slope of the linear regression (Fig.
5c), demonstrating that not all sets of mutations intrinsically
interfere with oligomeric organization, for Ile-40,Leu-41,Val-
44,Phe-45 VSV-SNAP-hD3 this effect was even more marked
(0.66 0.02-fold; mean S.E.) compared with wild type VSV-
SNAP-hD3 (Fig. 5d) (see later for statistical analysis of the full
data set).
In a similar manner mutants in TMD II generated based on
modeling of the receptorweremapped on to the receptor struc-
ture (Fig. 6a). htrFRET assays performed with the TMD II
quadruple mutant Tyr-88,Val-91,Thr-92,Asn-97 VSV-SNAP-
hD3 (Fig. 6b) revealed that the slope of the linear regression line
was also reduced compared with that for the wild type receptor
(0.68  0.07-fold of wild type; mean  S.E.) (Fig. 6b). Finally
within this set of experiments, cell surface delivery and
htrFRET assays performedwith the helix VIIImutants Phe-394
VSV-SNAP-hD3, Phe-394,Leu-395 VSV-SNAP-hD3, and Phe-
394,Leu-395,Lys-396 VSV-SNAP-hD3 (Fig. 6c) revealed that
the slope of the linear regression for each of these was reduced
compared with the wild type receptor (0.70 0.04, 0.60 0.12,
and 0.49 0.04; mean S.E., respectively) (Fig. 6d). However,
although the reduction in slope recorded for Phe-394,Leu-395
VSV-SNAP-hD3 was not significantly different from that
observed for Phe-394 VSV-SNAP-hD3, the effect on the slope
for Phe-394,Leu-395,Lys-396 VSV-SNAP-hD3 was signifi-
cantly greater than for Phe-394 VSV-SNAP-hD3 (Fig. 6d). This
indicates roles of both Phe-394 and Lys-396 in the formation of
an interface for hD3-hD3 interactions. Overall, these results
indicated an interface of oligomeric organization that involves
residues from both the extracellular and cytoplasmic side of
TMD I, the extracellular side of TMD II, and from helix VIII.
As supported by the results above, there is general accep-
tance that residues from TMD I, TMD II, and helix VIII can
provide either one of a number of means to generate a dimer of
many class AGPCRs or that these regions provide one interface
within a more complex homo-oligomeric structure (18, 25, 26,
33). To assess if further potential interfaces observed in crystal
structures of certain class AGPCRsmight be relevant to the cell
surface organization of the hD3, we generated further mutants
in VSV-SNAP-hD3 (Fig. 3). These were designed to provide
potential discrimination between the models shown in Fig. 1,
TABLE 1
[3H]Spiperone binding affinity of hD3 receptor mutants that display altered quaternary structure
The indicated hD3 receptor constructs were transiently expressed in HEK293T cells. Saturation [3H]spiperone binding studies were performed as described under
“Materials and Methods.” Data are presented as the mean S.E. NB, no specific [3H]spiperone binding detected over the concentration range employed.
Receptor variant
Ballesteros-Weinstein residue
numbering
[3H]Spiperone
binding KD
nM
VSV-SNAP-hD3 0.55 0.05
Arg-27,His-29,Leu-34,Cys-37 Arg-1.30,His-1.32,Leu-1.37,Cys-1.40 1.23 0.21a
Ile-40,Leu-41,Val-44,Phe-45 Ile-1.43,Leu-1.44,Val-1.47,Phe-1.48 NB
Tyr-88,Val-91,Thr-92,Asn-97 Tyr-2.63,Val-2.66,Thr-2.67,Asn-97 0.85 0.44
Arg-148,Leu-152,Val-159 Arg-4.40,Leu-4.44,Val-4.51, 2.47 0.40a
Arg-149,Leu-160 Arg-4.41,Leu-4.52 0.99 0.09a
Arg-210,Tyr-212 Arg-5.60,Tyr-5.62 1.60 0.14a
Leu-347,Thr-348,Leu-351 Leu-6.53,Thr-6.54,Leu-6.57 2.03 0.12a
Trp-370,Leu-371,Val-374 W7.40,Leu-7.41,Val-7.44 0.24 0.15a
Phe-394 Phe-8.54 1.63 0.18a
Phe-394,Leu-395,Lys-396 Phe-8.54,Leu-8.55,Lys-8.56 0.68 0.27
a Statistically different from VSV-SNAP-hD3.
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FIGURE4.Expressionandcell surfacedeliveryofVSV-SNAP-hD3variants.
a, lysates from HEK293T cells transiently transfected with an empty vector,
withVSV-SNAP-hD3 construct, or eachVSV-SNAP-hD3mutant variant of inter-
est were resolved by SDS-PAGE and immunoblotted (IB) with anti-SNAP anti-
serum (upper panel) or anti--tubulin antiserum (lower panel). b, HEK293T
cells transfected to express wild type VSV-SNAP-hD3 or each VSV-SNAP-hD3
mutant of interest were incubated with 10 nM SNAP-Lumi4-Tb; cell surface
binding was determined as described in Fig. 2.
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b–d. These centered on residues in each of TMDs IV,V, andVI.
Generally, for all themutants studied, a reduction of the expres-
sion level of the fully N-glycosylated form of the receptor was
observed compared with VSV-SNAP-hD3 (data not shown).
Reduction of cell surface expression of all of these variants was
also observed (data not shown). To consider a potential role for
TMD V residues, each of Asp-187,Ile-190,Val-194,Leu-199
(residue positions 5.37, 5.40, 5.44, and 5.49) VSV-SNAP-hD3,
based on contacts reflecting a -opioid receptor-like (26) (Fig.
1d) or a CXCR4-like (27) (Fig. 1c) dimer, or Arg-210,Tyr-212
VSV-SNAP-hD3 and Arg-210,Tyr-212,Val-213,Lys-216 VSV-
SNAP-hD3 (residue positions 5.60, 5.62, 5.63, and 5.66), based
on both -opioid receptor-like (26) (residues Tyr-212 and Lys-
216) and the 1-adrenoreceptor-like (25) (mainly Arg-210)
(Fig. 1b), possible arrangements (Fig. 7a) were then assessed in
htrFRET studies. Such studies indicated that the slope of the
linear regression of the 665-nm/620-nm correlation for the
quadruple mutant Asp-187,Ile-190,Val-194,Leu-199 VSV-
SNAP-hD3 was not significantly different from wild type (Fig.
7b). This suggests that this region does not play an important
role in hD3 receptor organization and, therefore, that organiza-
tion akin to that observed in the -opioid receptor and/or
CXCR4 receptor atomic level structures was unlikely. By con-
trast, a statistically significant effect on cell surface receptor
organizationwas observedwith the combination ofmutation of
Arg-210 and Tyr-212 (0.71  0.01-fold of wild type; mean 
S.E.; Fig. 7c). However, although the more extensive mutant
Arg-210,Tyr-212,Val-213,Lys-216 VSV-SNAP-hD3 was also
clearly impaired in oligomeric organization compared with
wild type, this mutant did not display further disruption com-
pared with the double Arg-210,Tyr-212 VSV-SNAP-hD3
mutant (Fig. 7c).
In the1-adrenoreceptor crystal dimer TMDV forms part of
a dimerization interface that also involves residues from TMD
IV (Fig. 1b). To assess this model for hD3, residues at the equiv-
alent positions in TMD IV predicted from the model, Arg-149
and Leu-160 (residue positions 4.41 and 4.52) or at Arg-148,
Leu-152, and Val-159 (residue positions 4.40, 4.44 and 4.51),
were mutated (Fig. 8a). After transient transfection, htrFRET
assays revealed that both Arg-149, Leu-160 VSV-SNAP-hD3
and Arg-148,Leu-152,Val-159 VSV-SNAP-hD3 had major
defects of quaternary structure organization (0.53 0.05- and
0.56 0.03-fold of wild type; mean S.E. respectively) (Fig. 8,
b and c). By contrast, in the-opioid receptor, TMDV is part of
a dimerization interface also involving residues located inTMD
VI. Therefore, we also generated the TMD VI mutant Leu-
FIGURE 5.Role of residues in TMD I in hD3-hD3 interactions. a, tertiary structure of hD3 receptor with TMD I residues that weremutated to alanine shown as
sticks. b–d, in each case the primary structure of TMD I is presented via the one-letter amino acid code. Amino acids that were replacedwith alanine are in bold
and are denoted by their position in the primary sequence of hD3. Asparagine residue 1.50 is also indicated. Representative htrFRET assays performed in
HEK293T cells transfected with increasing amounts of Arg-27,His-29,Leu-34,Cys-37 VSV-SNAP-hD3 (b, squares), Tyr-31,Tyr-32,Leu-34,Ser-35 VSV-SNAP-hD3 (c,
squares), or Ile-40,Leu-41,Val-44,Phe-45 VSV-SNAP-hD3 (d, squares) were compared with those performed on HEK293T cells transfected with increasing
amounts of VSV-SNAP-hD3 (b–d, circles). The plots shown were analyzed by linear regression. See Fig. 10 for analysis of the full data set.
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347,Thr-348,Leu-351 (residue positions 6.53, 6.54, and 6.57)
VSV-SNAP-hD3 (Fig. 9a) to mimic residues predicted by this
model to be buried upon dimer formation. Interestingly, and in
contrast to expectations from the -opioid receptor model,
based on the lack of effect of mutation (Asp-187,Ile-190,Val-
194,Leu-199 VSV-SNAP-hD3) of the extracellular side of TMD
V (Fig. 7b), htrFRET assays here revealed that Leu-347,Thr-
348,Leu-351 VSV-SNAP-hD3 caused a statistically significant
decrease (0.79 0.02-fold; mean S.E.) in the signal at 665 nm
compared with the wild type receptor at equivalent cell surface
expression levels (Fig. 9b).
As the htrFRET signal reduction observed for the TMD VI
mutant Leu-347,Thr-348,Leu-351 VSV-SNAP-hD3 and the
lack of effect of the TMD V mutant Asp-187,Ile-190,Val-
194,Leu-199VSV-SNAP-hD3 appeared to exclude either a pos-
sible -opioid receptor-like dimer arrangement (Fig. 1d) or a
CXCR4-like arrangement (Fig. 1c), we considered other possi-
ble hD3 oligomer arrangements including those that predict
tetrameric organization. Recently, mathematical analysis of
spectrally resolved multi-photon FRET microscopy data has
provided evidence that a substantial proportion of the human
M3 muscarinic acetylcholine receptor is present at the surface
of transfected cells as a tetramer with rhombic organization
(39). Moreover, as in-house data had shown a specific role for
both TMDVII and TMDVI in organization of the tetramer via
cholesterol molecules that bridge a pair (dimer  dimer) of
TMD I-helix VIII interface M3 muscarinic receptor dimers
(40), we generated both additional mutants and models of
potential organization of the hD3, akin to these muscarinic
M3 models, to explore if these could unify the experimental
observations.
Based on these models a TMD VII mutant Trp-370,Leu-
371,Val-374 (residue positions 7.40, 7.41, and 7.44), VSV-
SNAP-hD3 was produced (Fig. 3) and studied (Fig. 9, c and d).
Both total (not shown) and cell surface expression level of Trp-
370,Leu-371,Val-374 VSV-SNAP-hD3 were reduced compared
with wild type. Although expressed poorly at the cell surface,
htrFRET studies again generated a linear regression for oligo-
merization versus cell surface expression. Most importantly,
the slope of the linear regression for Trp-370,Leu-371,Val-374
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VSV-SNAP-hD3 was reduced markedly (0.53  0.07-fold;
mean  S.E.) compared with the wild type hD3 receptor (Fig.
9d). These results, which are not predicted by any of the crystal
structure dimer models are, however, fully consistent with the
rhombic tetramer model. Mapping of the full htrFRET experi-
mental data set (Fig. 10) back to such a model also resulted in
predictions of effects of mutants as observed from the experi-
mental studies (see “Discussion”).
Discussion
There are five distinct, but highly related (D1–5), receptors
that respond selectivity to the catecholamine dopamine. These
have been reported to form both homomers and heteromers
with partners within this subfamily (12, 13, 15, 36, 41) and also
with GPCRs, which respond to different ligands, for example,
receptors for adenosine (42). At the level of homomeric inter-
actions there has been particular focus on members of the
D2-like subfamily (D2, D3, and D4). The capacity of the dop-
amine D2 receptor to form homodimers and higher order olig-
omers in living cells has been studied extensively by Javitch and
co-workers (16–18). A symmetric interface of hD2 receptor
dimerization was described as involving TMD IV in the active
state of the receptor and both TMD IV and TMD V in the
inactive (16, 17). However, the quaternary structure for hD2
receptor has also been suggested to be composed of at least four
protomers in which interactions occur both between residues
from TMD IV and TMD V and by residues at the extracellular
site of TMD I and residues from helix VIII (18). Although the
high relatedness of D2 and D3 receptors might suggest similar
means of generating homomeric interactions, this has not been
assessed directly, and much less is known about the basis of D3
receptor homo interactions. Therefore, in the current studies
the use of computationalmodels and experimental studieswere
combined to investigate these questions. Residues predicted as
possibly being involved at oligomer interfaces were assessed by
use of alanine mutagenesis, and their effect was measured by
use of htrFRET assays employing Tag-LiteTM technology (21).
As the Tag-LiteTM htrFRET energy acceptor and donor moi-
eties are not cell-permeant and link covalently to the SNAP tag
that was introduced into the extracellular N-terminal domain
of wild type VSV-SNAP-hD3 and the various receptor mutants
studied, signals reflected only cell surface-delivered receptors.
Indeed, measuring fluorescence emission of SNAP-Lumi4-Tb
at 620 nm after excitation at 337 nm provided a direct measure
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of cell surface expression without concern that the mutations
might affect the affinity of radioligands in direct binding stud-
ies. Despite this, we also assessed the possible effects of the
mutations on the affinity of the constructs to bind the antago-
nist [3H]spiperone. Only a single TMD Imutant showed a large
change in affinity for this ligand. The one mutant we describe
that lost affinity for [3H]spiperone to the extent that wewere no
longer able to measure this effectively was Ile-40,Leu-41,Val-
44,Phe-45 (1.43, 1.44, 1.47, 1.48) VSV-SNAP-hD3, one of the
most extensive mutants we generated. Here four predomi-
nantly hydrophobic residues were each altered to alanine.
These are located in the middle of TMD I. Based on a variety of
atomic level structures, TMD I is not routinely an element that
makes specific interactions with small molecule ligands, and
indeed, in the available atomic level structure of theD3 receptor
eticlopride does not interact directly with these residues (20).
As such, a potential explanation for the loss of affinity of
[3H]spiperone for thismutantmust be speculative. However, as
defined in the models, Leu-1.44 interacts both with the same
residue of the other protomer and with Ile-1.43, Val-1.47, and
Phe-1.48 via a cholesterol molecule. Disruption of the contri-
bution of cholesterol, a key overall element of the models we
generated, may be vital to the effect on ligand binding. It is
worth noting, however, that although we were unable to
directly measure the affinity of [3H]spiperone for this mutant,
clearly it does still bind this ligand with significant affinity
because treatment of cells with non-radiolabeled spiperone
promotes more effective cell surface delivery of the expressed
mutant,6 a feature generally referred to as a “pharmacological
chaperone” effect. This requires the receptor variant to be able
to bind the ligand in question. The other mutants, with the
possible exception of Arg-148,Leu-152,Val-159 VSV-SNAP-
hD3, displayed onlymodest effects, indeed nomore than 4-fold,
on the measured binding affinity of [3H]spiperone. Even these
measured differences may represent something of an artifact.
Measures of binding affinity can bemodified if expression levels
of receptor variants are markedly different, and the results of
6 S. Marsango and G. Milligan, unpublished information.
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Fig. 4 show that this was clearly the case for a number of the
mutants studied.
The SNAP-tag approach proved to be vital for analysis as
virtually all of the receptor mutants studied were delivered to
the cell surface of transfected cells less well than the wild type
receptor construct.However, quantification of the extent of cell
surface delivery allowed measurement of energy transfer and,
therefore, comparison of protein-protein interaction effective-
ness, at equal levels of cell surface expression.
Despitemany of the hD3 variants displaying significant alter-
ation in protein-protein interactions, for none of these was
homo-oligomerization completely ablated. We considered a
number of scenarios that could account for this. First, as vari-
ants that were more extensive than quadruple point mutants
were simply not expressed at the cell surface, it was possible
that we had only targeted part of more extended interacting
dimer surfaces. Second, as experimental data and crystal struc-
tures suggested the potential for multiple dimer interfaces,
mutations in a single TMD might disrupt only a subset of the
existing dimers. However, because we showed directly that at
least two different interfaces of dimerization exist for the hD3
and because bothwe and others have shown that classAGPCRs
can form higher order oligomers (18, 38, 43–45), we also con-
sidered if such models could provide a single, coherent expla-
nation for the overall data set.
Although crystal structures of class A GPCRs show different
interfaces to be involved in dimer organization, a rather con-
served interface, involving TMD I, TMD II, and intracellular
helix VIII is a routine feature (25–26, 33–34). Amodel of a hD3
homodimer based on this arrangement is shown in Fig. 11, cen-
tral panel, and compared with the observed structure of the
1-adrenoreceptor. Generating the Arg-271.30,His-291.32,Leu-
341.37,Cys-371.40 mutant in the extracellular side of TMD I and
Tyr-882.63,Val-912.66,Thr-922.67,Asn-97w1 at the top TMD II
(Asn-97 is part of extracellular loop 1 rather than within the
TMD), which were predicted to form a hydrogen-bond net-
work that stabilizes hD3-hD3 interactions (Fig. 11, inset (i))
showed that both sets of alterations had a substantial impact on
the quaternary structure of the receptor. Of note, residues at
similar positions in both TMD I, namely, Gln-1.29 (position
1.30 is an alanine), Glu-1.32, Leu-1.37, and Ala 1.40 as well as in
TMD II Thr-2.63, Val-2.66, and Arg-2.67 and a leucine one
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residue after the strongly conserved tryptophan (W1) (46) in
external loop 1, have been shown to form a packed interaction
in the 1-adrenoreceptor (25). As studies on hD2 receptor
dimerization have indicated that residues at positions 1.34,
1.35, and 1.38 have an active role (18), we also investigated the
effect of mutating the sequence Tyr-311.34,Tyr-321.35, Leu-
341.37,Ser-351.38 on hD3 interactions. However, this variant was
both well expressed at the cell surface and showed no disrup-
tion of quaternary organization. Indeed, our model does not
predict a role for these residues in the hD3 receptor (Fig. 11) as
these either face TMDVII of the same protomer (Tyr-321.35) or
face the external side close to it (Tyr-311.34 and Ser-351.38).
Further work on the D2 receptor will be needed to understand
these potential discrepancies. Ourmodels also predicted possi-
ble roles of residues in the lower half and toward the cytoplas-
mic end of TMD I. A strong effect on both the surface expres-
sion level and on quaternary structure of hD3 receptor was
indeed observed for the mutant Ile-401.43, Leu-411.44, Val-
441.47, Phe-451.48 hD3. Although an important role of leucine
1.44 can be explained via a symmetrical hydrophobic interac-
tion with the same residue in the other protomer (Fig. 11, inset
(ii)), as was also observed in the 1-adrenoreceptor dimeric
crystal (25), contribution of the residues at position 1.43 (Ile-
40), 1.47 (Val-44) and 1.48 (Phe-45) cannot be explained via
direct interaction between the two protomers. However, the
corresponding residues in these positions are involved in bind-
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FIGURE 11.Molecularmodeling of potential dimeric arrangement: the TMD I-TMD II-helix VIII interface. Center panel, general view of amodel of an hD3
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ing amolecule of cholesterol in the crystal structures of both the
2-adrenoreceptor (34) and the serotonin 5-HT2B receptor
(47), and a molecule of cholesterol in this location in the hD3
would provide a bridge between the helices of the two proto-
mers (Fig. 11, inset (ii)). Moreover, the contribution of choles-
terol and/or other lipid molecules to GPCR organizational
structure may be widespread, as further structures of class A
GPCRs contain other, sometimes structurally conserved, mol-
ecules of cholesterol. Moreover, in an experimental paradigm
Oates et al. (48) have shown cholesterol to influence activity,
stability, and oligomerization of the neurotensin NTS1 recep-
tor. Finally, the dimer of the seven TMD region of the class C
metabotropic glutamate receptor 1 (49) shows cholesterolmol-
ecules making a specific contribution to the receptor-receptor
interface. Such data and observations resulted in us explicitly
considering the possible importance of cholesterol molecules
in our models by adding them to hD3 monomeric units (see
“Materials and Methods”). Of course these suggestions of spe-
cific roles for molecules of cholesterol are inherently specula-
tive, not the least because means to deplete specific molecules
of cholesterol, rather than the bulk cholesterol population, are
lacking.Despite this, the implications of the identified positions
ofmolecules of cholesterol inGPCR structures is intriguing and
worthy of further investigation.
As noted earlier, a number of studies have implied roles for
elements of the intracellular helix VIII in GPCR dimer interac-
tions. Alanine mutation of Phe-3948.54 in hD3 receptor pro-
duced a substantial effect on quaternary structure without
altering cell surface expression of the receptor. This effect was
further increased with the simultaneous mutation of Leu-
3958.55 and Lys-3968.56. Residues at position 8.54, 8.55, and 8.56
in both 1-adrenoreceptor and in -opioid receptor structures
have also been observed to be part of the extended TMD
I-TMD II-helix VIII interface (25, 26).
In contrast to the rather conserved interface involving TMD
I-TMD II, and helix VIII, less conserved interfaces are observed
in crystal structures on the “opposite” side of the receptor TMD
bundle, although each of these points to a pivotal role of TMD
V. hD3 receptor variants in this helix were engineered that
simultaneously substituted those residues predicted to be selec-
tively involved only in one of the TMD V-based dimers
observed in the atomic level structures. A hD3 dimer with
CXCR4-like organization (27) predicted TMDV residues Asp-
1875.37,Ile-1905.40,Val-1945.44,Leu-1995.49 to be crucial for the
interface. However, the htrFRET signal per copy of cell surface
receptor for this mutant was not different from wild type, thus
excluding this type of organization. In a similar way, a hD3
dimer organized with a -opioid receptor-like TMD V-TMD
VI configuration (26) was also excluded because the crystal
structure and models indicated a role for Asp-1875.37 (already
noted from theCXCR4-likeTMDVmutant not to be an impor-
tant contributor) as well as from Tyr-2125.62 and Lys-2165.66.
The addition of alanine substitutions of both Leu-2135.63 and
Lys-2165.66 into a mutant (Arg-2105.60 and Tyr-2125.62 hD3)
that had a strong effect to reduce the htrFRET signal did not
result in further reduction of the htrFRET signal. By contrast,
the mutagenesis studies were most consistent with an hD3
dimer organization akin to that observed for the 1-adrenore-
ceptor (25). Such a 1-adrenoreceptor-like configuration indi-
cated roles of residues from both TMDV (in particular residue
Arg-2105.60) and TMD IV. Indeed, mutation of residues Arg-
1484.40, Arg-1494.41, Leu-1524.44, and Val-1594.51, Leu-1604.52
in TMD IV had large effects on hD3 receptor quaternary orga-
nization. Involvement of TMD IV and TMD V in GPCR qua-
ternary structure has also been predicted from biochemical
studies. For example, when investigating the basis of hD2
homodimer interactions using a chemical cross-linking
approach, residues from TMD IV (including Arg-4.41, Val-
4.44, Val-4.51, Leu-4.52, which are equivalent to Arg-149, Leu-
152, Val-159, and Leu-160 in hD3) and TMD V were described
as important in maintaining the stability of the hD2-hD2 inter-
action (17). Similarly for the -opioid (50) and 5-HT1A (51)
receptors, residues at positions 4.40 and 4.41 (equivalent to
Arg-148 and Arg-149 in hD3) were shown to be part of a sug-
gested TMD IV-TMD V interface. Furthermore, the P2Y12
purinoceptor (35) may also form a TMD V dimer mediated by
cholesterol molecules. Indeed, the predicted hD3 model, based
on 1-adrenoreceptor TMD IV-TMD V dimer organization, is
consistent with a cholesterol-mediated dimer. Mutants that
reduced the htrFRET signal, including residues Arg-1484.40,
Leu-1524.44, and Val-1594.51 in TMD IV as well as Arg-2105.60
from TMD V, are compatible with an interaction involving a
cholesterol molecule in the equivalent position as found in the
P2Y12 purinoceptor structure (Fig. 12).
These results thus can account for at least two different
dimeric arrangements of hD3 receptor, both in broad agree-
ment with those observed in the 1-adrenoreceptor crystal
structure (25). Based on such dimer interfaces, we constructed
models of possible tetrameric organization resulting from
dimer  dimer contacts and examined predictions that might
discriminate between these by considering both rhombic and
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FIGURE 12. Molecular modeling of potential dimeric arrangement: the
TMD IV-TMDV interface. Left panel, general view of a model of a hD3 dimer
that employs residues fromTMD IV and TMDV (opaque light and dark gray) as
interacting surfaces (upper panel) and organized with a 1-adrenoreceptor-
like arrangement (lower panel). Residues in gray sticks when mutated to ala-
nine induce htrFRET reduction; yellow sticks indicate a possible cholesterol
moleculemediating the interactionbetweenprotomers.Right panel, detail of
the interaction between protomers. Residues of TMD IV extensively interact
with a cholesterol molecule, positioned as observed in the P2Y12 receptor
atomic level structure, whereas only Arg-5.60 is actively involved in this inter-
acting interface (indeed adding Val-5.63 and Lys-5.66 to the Arg-5.60 and
Tyr-5.62 mutant did not further reduce htrFRET).
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“linear” tetramer models. Both TMD I-TMD II-helix VIII and
TMD IV-TMDV interfaces can be simultaneously involved in a
linear dimer dimer (as hypothesized for the 1-adrenorecep-
tor (25) and for the -opioid receptor (26)), and importantly,
residues from other TMDs are not required to allow such orga-
nization. By contrast, this is not the case in rhombic dimer 
dimer organization, which also requires contributions of other
helices. We thus built possible rhombic dimer  dimer tetra-
mers based on shape complimentarily of the monomer of the
antagonist-bound inactive D3 receptor structure. The models
that incorporated pairs of dimers in which each dimer interface
was between TMD IV and TMD V resulted in forms that were
unable to simultaneously bind two heterotrimeric G proteins
in their nucleotide “empty” configuration (see “Materials
and Methods”).
When employing TMD I-TMD II-helix VIII interface dimers
a tightly packed rhombic tetramer was produced (Fig. 13, cen-
tral panel). This complex could simultaneously bind two het-
erotrimeric G proteins in their nucleotide-free form. Signifi-
cantly this model (Fig. 13, inset (ii)) predicted an important role
forTMDVbut, rather than at the protomer-protomer interface
of the individual dimers, its role was at the dimer  dimer
interface of the rhombic tetramer. This model shows choles-
terol binding to the lower part of TMD I and mediating an
interaction of TMD I from one dimer with TMD V from the
seconddimer that specifically involves residuesArg-2105.60 and
Tyr-2125.62 (Fig. 13, inset (ii)). Mutation of these residues dis-
rupted quaternary organization at the cell surface. Perhaps
evenmore significantly, themost extensive predicted “dimer
dimer” interface in the rhombic tetramer model involved resi-
dues from TMD VI and from TMD VII (Fig. 13). No role of
TMDVI andTMDVII in hD3 quaternary structure is predicted
in the linear tetramer model involving the two dimer interfaces
we found experimentally. These predictions allowed direct
experimental comparison of linear versus rhombic tetramer
models, as they predicted markedly different outcomes for
mutants in TMDVI and TMDVII on htrFRET signal and qua-
ternary structure. The TMD VI mutant Leu-3476.53,Thr-
3486.54,Leu-3516.57 and, particularly, theTMDVIImutant Trp-
3707.40,Leu-3717.41,Val-3747.44 displayed marked reduction in
hrtFRET signal, consistent with these alterations affecting qua-
ternary structure and, therefore, providing support for the
rhombic tetramer model.
Interestingly, two molecules of cholesterol that interact with
TMD VI at its extracellular side in the rhombic tetramer con-
structs create a layer of four cholesterol molecules that line up
to form a “buffer” between the dimers (Fig. 13). Of note, a cho-
lesterol located at the extracellular side of TMD VI in an aden-
osine A2A receptor crystal (52) is superimposed, after building
the rhombic tetramer hD3 model, with the cholesterol
observed on the extracellular side of TMD VII of the P2Y12
receptor (36). A possible direct TMDVI-TMDVII dimer was
also dismissed from further consideration both because such
hypothetical dimers would impede the well known outward
displacement of TMD VI upon ligand-induced activation
and subsequent heterotrimeric G protein coupling and
because such an interface has not been observed in any crys-
tal structure to date. Interestingly, Leu-3717.41 and Val-
3747.44 lie deep in the concave spot of helix TMD VII, a
location from which they would be unlikely to form direct
residue-residue interactions with TMD VI. However, the
model predicts they can do so via the tail of an intermediate
molecule of cholesterol (Fig. 13, inset (i)).
Taken together, these results suggest not only the capability
of hD3 to form dimers but also higher order oligomers in which
four protomers are predicted to organize in a rhombic arrange-
ment. It is notable, therefore, that mathematical analysis of
FRET efficiency peaks taken from spectrally resolved, multi-
photon imaging of cells expressing a pair of FRET-competent
forms of theM3muscarinic acetylcholine receptor has also pre-
dicted that a substantial proportion of the receptor is organized
within such rhombic tetramers (39). It also suggests whymuta-
tions in a single TMD are unable to result in elimination of
htrFRET signal.
Whether this is the basic default position of class A GPCRs
in general remains to be established, as does the stability of
such tetramers and their importance for allosteric ligand
effects and, potentially, for ligand signaling and bias. If these
are not stable complexes, and certain studies have suggested
that GPCR “dimers” may rapidly associate and then dissoci-
ate (53, 54), then information generated in these studies may
be utilized to develop peptides able to selectively disrupt
dimers, as in studies on the secretin receptor (55), or tetra-
mers, providing the possibility to assess their functional rel-
evance in living cells.
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FIGURE13.MolecularmodelingofhD3 in tetramericarrangements.ModelofhD3 ina tetrameric arrangementas result of adimerdimer interactions. Each
dimer is shown as a semi-transparent surface, whereas predicted cholesterols are shown as yellow spheres forming a buffer between the two dimers. Inset (i)
shows details of the TMD VI and TMD VII interface, and the residues shown in sticks (gray and light blue) were found experimentally to affect hD3 quaternary
structure.Yellow sticks and spheresdepict predicted cholesterolmolecules in positions as observed in adenosineA2A receptor,-opioid receptor, and the P2Y12
receptor structures. Inset (ii) shows details of the predicted interaction between TMD V Arg-5.60 and Tyr-5.63 (in gray sticks) of one dimer and the TMD I
cholesterol (in yellow sticks and spheres). A predicted palmitoyl moiety, bound to Cys-8.60, is also shown inmagenta semi-transparent sticks.
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